Boehringer Ingelheim: Lung Diseases, Interstitial trials

The registry lists 24 Lung Diseases, Interstitial studies with Boehringer Ingelheim as lead sponsor. 4 are open to participants now and 11 have results posted.

Phase 3 11No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease ProgressionRecruitingNCT07540988Phase 3
• A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)RecruitingNCT07366034Phase 3
• A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisRecruitingNCT07201922Phase 3
• Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)RecruitingNCT05819385
• Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung DiseaseCompletedNCT05957198Results posted
• Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and TreatmentCompletedNCT05875532Results posted
• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)CompletedNCT05321082Phase 3Results posted
• A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)CompletedNCT05285982Phase 3Results posted
• A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung FibrosisCompletedNCT05065190Phase 3Results posted
• INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world EvaluationCompletedNCT04702893Results posted
• Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in JapanCompletedNCT04559581Results posted
• A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)CompletedNCT04093024Phase 3Results posted
• A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)CompletedNCT03820726Phase 3Results posted
• A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung FibrosisCompletedNCT03313180Phase 3Results posted
• Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)CompletedNCT02999178Phase 3Results posted
• A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung FibrosisActive, not recruitingNCT07080125
• A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic DiseasesActive, not recruitingNCT06806592Phase 3
• Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk FactorsCompletedNCT05855109
• Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) PatientsTerminatedNCT05503030
• A Study to Test Different Imaging Techniques in Patients With Different Types of Interstitial Lung DiseaseCompletedNCT05492994Not applicable
• INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world EvaluationCompletedNCT05151640
• An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment OptionsNo longer availableNCT04739150
• Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in JapanCompletedNCT04325217
• An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment PossibilitiesApproved for marketingNCT03843892